BMJ open
-
Meta Analysis
Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis.
Evaluation of remdesivir, an RNA polymerase inhibitor, for effectiveness in adults with COVID-19. ⋯ As per the evidence from current review, remdesivir has shown no mortality benefit (moderate quality evidence) in the treatment of COVID-19. From a cost-benefit perspective, it is our personal opinion that it should not be recommended for use, especially in low and lower middle income countries.